IL-6，CAl9—9和CA242在胰腺癌诊断和临床分期中的应用  

Application of IL-6,CA19-9 and CA242 in the Diagnosis and Clinical Staging of Pancreatic Cancer

作　　者：钟善传[1] 董凤珍[1] 刘涤瑕[1] 王丽[1] 涂晖[1] 陈金超[1] 

机构地区：[1]中国人民解放军第532医院,安徽黄山245041

出　　处：《现代检验医学杂志》2011年第4期56-58,共3页Journal of Modern Laboratory Medicine

摘　　要：目的探讨单独或联合检测血清IL-6，CAl9—9和CA242在胰腺癌诊断中的价值，分析3项肿瘤标志物血清水平与胰腺癌临床分期的关系。方法分别检测83例胰腺癌患者、78例慢性胰腺炎患者和80例健康者血清中IL-6，CAl9—9和CA242水平，分析3种指标对胰腺癌诊断的临床价值及其与临床病理因素之间的关系。结果在胰腺癌病人中，3种标志物血清浓度均显著高于慢性胰腺炎组和对照组；并且与肿瘤的浸润程度、淋巴结转移以及远处转移相关。3种标志物平行法联合检测可使诊断的灵敏度提高至95．2％，系列法联合检测则使特异度提高至97．5％。结论血清IL－6，CAl9—9和CA242水平对胰腺癌的诊断和临床分期具有重要意义，联合检测可提高诊断灵敏度和特异度。Objective To explore the value of single or combined detection of serum IL-6,CA19-9 and CA242 in the diagnosis of pancreatic cancer and analyze the relationship between these 3 markers and the clinical stage of pancreatic cancer. Methods The levels of IL-6,CA19-9 and CA242 in the serum of human pancreatic cancer group（83 cases） ,chronic pancreatitis patients （78 cases） and healthy controls （80 cases） were determined and their relationship with clinical pathological parameters of patients with pancreatic cancer was analysed. Results In pancreatic cancer patients ,the serum concen-trations of all these proteins tested were significantly higher than chronic pancreatitis patients and healthy controls,and were correlated with tumor size,nodal metastases and distant metastases. Method of parallel combined testing could increase the diagnostic sensitivity to 95.2%,and serial combined examination could increase the diagnostic specificity to 97.5%. Conclusion Serum IL-6,CA19-9 and CA242 were significant factors for the diagnosis and clinical staging of patients with pancreatic cancer ,and combined detection of these markers could increase the sensitivity and specificity in the diagnosis of pancreatic cancer.

关 键 词：胰腺癌 肿瘤标志物 白细胞介素-6 糖蛋白抗原19—9 糖蛋白抗原242 

分 类 号：R735.9[医药卫生—肿瘤] R730.43[医药卫生—临床医学]